Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) has received an average rating of “Hold” from the seven ratings firms that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and four have given a buy recommendation to the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $10.65.

A number of equities research analysts have recently commented on the company. BidaskClub downgraded Tetraphase Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, August 10th. Zacks Investment Research raised Tetraphase Pharmaceuticals from a “hold” rating to a “buy” rating and set a $6.25 price target for the company in a research report on Wednesday, August 9th. Needham & Company LLC reissued a “hold” rating on shares of Tetraphase Pharmaceuticals in a research report on Thursday, July 27th. BMO Capital Markets reissued an “outperform” rating and set a $13.00 price target (up previously from $12.00) on shares of Tetraphase Pharmaceuticals in a research report on Wednesday, July 26th. Finally, Stifel Nicolaus raised Tetraphase Pharmaceuticals from a “hold” rating to a “buy” rating and boosted their price target for the company from $8.00 to $15.00 in a research report on Wednesday, July 26th.

Tetraphase Pharmaceuticals (NASDAQ TTPH) opened at 5.77 on Monday. The stock’s market capitalization is $294.58 million. The stock’s 50 day moving average price is $6.69 and its 200-day moving average price is $7.01. Tetraphase Pharmaceuticals has a 12-month low of $3.11 and a 12-month high of $9.93.

Tetraphase Pharmaceuticals (NASDAQ:TTPH) last announced its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported ($0.83) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.76) by $0.07. The business had revenue of $1.59 million during the quarter, compared to analysts’ expectations of $1.54 million. Tetraphase Pharmaceuticals had a negative net margin of 2,092.20% and a negative return on equity of 79.79%. Tetraphase Pharmaceuticals’s revenue for the quarter was up 28.2% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.47) EPS. Analysts expect that Tetraphase Pharmaceuticals will post ($2.55) earnings per share for the current year.

Large investors have recently bought and sold shares of the stock. State Street Corp increased its stake in Tetraphase Pharmaceuticals by 1.6% in the fourth quarter. State Street Corp now owns 710,982 shares of the biopharmaceutical company’s stock worth $2,864,000 after buying an additional 11,391 shares during the period. Dimensional Fund Advisors LP increased its stake in Tetraphase Pharmaceuticals by 580.4% in the fourth quarter. Dimensional Fund Advisors LP now owns 226,222 shares of the biopharmaceutical company’s stock worth $912,000 after buying an additional 192,972 shares during the period. Teachers Advisors LLC increased its stake in shares of Tetraphase Pharmaceuticals by 20.1% in the fourth quarter. Teachers Advisors LLC now owns 75,844 shares of the biopharmaceutical company’s stock valued at $306,000 after buying an additional 12,691 shares during the last quarter. Nationwide Fund Advisors increased its stake in shares of Tetraphase Pharmaceuticals by 148.2% in the first quarter. Nationwide Fund Advisors now owns 60,622 shares of the biopharmaceutical company’s stock valued at $557,000 after buying an additional 36,200 shares during the last quarter. Finally, Acadian Asset Management LLC increased its stake in shares of Tetraphase Pharmaceuticals by 108.2% in the first quarter. Acadian Asset Management LLC now owns 379,049 shares of the biopharmaceutical company’s stock valued at $3,482,000 after buying an additional 197,022 shares during the last quarter. 35.93% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: “Tetraphase Pharmaceuticals, Inc. (TTPH) Receives Average Rating of “Hold” from Brokerages” was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this report on another site, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The legal version of this report can be accessed at https://www.thecerbatgem.com/2017/08/21/tetraphase-pharmaceuticals-inc-ttph-receives-average-rating-of-hold-from-brokerages.html.

About Tetraphase Pharmaceuticals

Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.

Analyst Recommendations for Tetraphase Pharmaceuticals (NASDAQ:TTPH)

Receive News & Stock Ratings for Tetraphase Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.